Table 2

HLA alleles in patients with MOGADs and in healthy controls

HLA allelePatients (n=95 × 2)Controls (n=481 × 2)P valuePadj valueOR (95% CI)
PositiveNegativeFreqPositiveNegativeFreq
DQB1*05:02361540.18951038590.10710.00230.03161.95 (1.25 to 3.00)
DPB1*13:0171830.0368828800.08520.02460.11050.41 (0.16 to 0.91)
DRB1*08:0341860.0211698930.07170.00550.12780.28 (0.07 to 0.76)
DRB1*16:02171730.0895419210.04260.01060.12782.21 (1.15 to 4.08)
DPA1*02:02124660.65265504120.57170.04380.17541.41 (1.01 to 1.98)
DQA1*01:02511390.26841927700.19960.04070.22151.47 (1.01 to 2.13)
DQA1*01:0371830.0368798830.08210.03320.22150.43 (0.16 to 0.94)
DRB1*14:0581820.0421169460.01660.04460.26752.60 (0.95 to 6.54)
DRB1*15:02111790.0579269360.02700.03970.26752.21 (0.97 to 4.73)
DQB1*05:03151750.0789409220.04160.03850.26971.97 (0.99 to 3.75)
C*07:02221680.11581717910.17780.04290.31440.61 (0.36 to 0.98)
C*06:0221880.0105389240.03950.04930.31440.26 (0.03 to 1.02)
A*02:07341560.17891198430.12370.04650.46831.54 (0.98 to 2.37)
  • Table shows only HLA alleles with an unadjusted p value of <0.05. P values are adjusted for multiple testing via the FDR step-up method.

  • FDR, false discovery rate; freq, frequency; HLA, human leucocyte antigen; MOGADs, myelin oligodendrocyte glycoprotein-associated disorders.